You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 306 Evaluation of AB-101, an allogeneic cord blood-derived natural killer (NK) cell therapy, as an ADCC enhancer in hematologic and solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cell Therapies
306 Evaluation of AB-101, an allogeneic cord blood-derived natural killer (NK) cell therapy, as an ADCC enhancer in hematologic and solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to March 2024

AbstractFullPdf
Nov 20221020059
Dec 2022257029
Jan 2023124017
Feb 2023146029
Mar 2023136016
Apr 2023154010
May 2023118019
Jun 202372012
Jul 202346010
Aug 202393014
Sep 202360015
Oct 20237606
Nov 20237408
Dec 2023110018
Jan 20245002
Feb 20249009
Mar 202480016
Total27060289